research papers

Recruitment and Active Studies

The Lakeside Healthcare Research and Innovation Unit has been set up to provide all our patients with the opportunity to take part in clinical research studies which are relevant to them.

Recruitment

MOVe-NOW clinical study

This study will be testing an investigational medicine for COVID-19.

Investigators want to see how well it may work and if it is safe in adults with COVID-19 who are more likely to have serious symptoms from COVID-19.

You may be able to take part in this study if you are 18 years or older and:

  • have a health condition that may make you more likely to become very sick from COVID-19
  • are not in hospital for any reason

There are more requirements, which the study doctor will discuss with you. You do not need to currently have COVID-19 to consider taking part in this study.

If you test positive for COVID-19, you will:

  • be in the study for about 6 months
  • visit the study clinic about 7 times
  • have about 3 virtual (video or phone) visits with the study team

There is no cost to take part in this study. Reimbursement may be available for your study-related travel expenses.

To find out more, including the possible risks and benefits of being in this study, please contact us.

AstraZeneca Tharros

A Study Evaluating the Efficacy of Breztri/Trixeo on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease.

THARROS is a clinical study looking at whether treatments for COPD may help prevent COPD flare-ups and serious heart events, like heart failures and heart attacks. We understand the impact COPD has on your daily life so we’ve made it easy to get involved. You could have most of your visits over video call and get study treatment delivered to your door. 

To find out more, including the possible risks and benefits of being in this study, please contact us.

Amgen Asthma

A phase 2 study of Rocatinlimab in moderate -to- severe asthma in Adults.

To find out more, including the possible risks and benefits of being in this study, please contact us.

Bellus Calm 2

The CALM-2 Study is looking at a potential new drug (an investigational drug) for the treatment of refractory chronic cough (RCC), including unexplained chronic cough.

The aim of this study is to see how safe the investigational drug is and whether it works in people with RCC.

We plan to enrol a wide variety of participants because RCC and treatments may affect people differently based on their age, sex, gender, and race and/or ethnicity. We are looking for adults who:

  • are between 18 and 80 years of age
  • have had a cough for at least 1 year that did not improve or only partially improved after medical evaluation and prescribed or over-the-counter treatments.

To find out more, including the possible risks and benefits of being in this study, please contact us.

Sanofi Airlympus study

The AIRLYMPUS study is testing an investigational study drug to see if it can improve breathing and symptoms of asthma and reduce future asthma attacks.

The AIRLYMPUS study is testing an investigational study drug to see if it can improve breathing and symptoms of asthma and reduce future asthma attacks when taken with standard asthma background therapy.

You may be eligible if you:

  • Are 18 to 80 years of age
  • Have had a diagnosis of asthma for at least 12 months
  • Had at least one asthma attack in the last year
  • Are taking daily treatment for your asthma
  • Additional criteria apply.

If you qualify for the study you will receive study-related treatment, tests and doctor visits at no cost to you. You may be in the study for up to 64 weeks.

To find out more, including the possible risks and benefits of being in this study, please contact us.

Current Studies

Lakeside Healthcare Research and Innovation Unit

  • AstraZeneca Flash - A Phase 2a, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of Atuliflapon given orally once daily for twelve weeks in adults with moderate-to-severe uncontrolled asthma.
  • AstraZeneca Prospero - A Phase III, multicentre, randomised, double-blind, chronic-dosing, parallel-group, placebo-controlled extension study to evaluate the long-term efficacy and safety of Tozorakimab in participants with chronic obstructive pulmonary disease (COPD) with a history of COPD exacerbation.
  • AstraZeneca SOLSTICE - A Phase IIb, randomized, double-blind, placebo-controlled, and open-label active comparator study to evaluate the efficacy, safety, and tolerability of AZD5004 in adults with type 2 diabetes mellitus.
  • Bellus Calm-1 - A Phase 3, 52-week, randomized, double-blind, placebo-controlled, parallel-arm efficacy and safety study with open-label extension of BLU-5937 in adult participants with refractory chronic cough, including unexplained chronic cough.
  • Moderna CMVictory - A phase 3 vaccine study. Testing a new investigational vaccine (mRNA-1647) for its safety and effectiveness in preventing CMV in healthy adult females.
  • Moderna Nova - A Phase 3, randomized, observer-blinded, placebo-controlled study to evaluate the safety and efficacy of mRNA-1403, a multivalent candidate vaccine to prevent norovirus acute gastroenteritis in adults aged ≥18 years
  • MSD MK00616-015 - A Phase 3, randomised, placebo-controlled clinical study to evaluate the efficacy and safety of MK-0616 in reducing major adverse cardiovascular events in participants at high cardiovascular risk.
  • Novartis Victorion - 1 Prevent - A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients.
  • Novo Nordisk Zeus - A research study to look at how Ziltivekimab works compared to placebo in people with cardiovascular disease, chronic kidney disease and inflammation.